- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07836452
A Phase 1, First-in-Human Study of CITY-RBP4 in Healthy Volunteers and STGD1 Participants
A Phase 1, Randomized, Double-Masked, Placebo-Controlled, Single-Ascending and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CITY-RBP4 Administered Subcutaneously in Healthy Volunteers and Participants With Stargardt Disease Type 1 (STGD1)
This is a first-in-human (FIH), multicenter, randomized, double-masked, placebo-controlled adaptive clinical study evaluating the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) of CITY-RBP4, following single-ascending doses and multiple doses, via subcutaneous (SC) administration.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
The study consists of 3 sequential parts:
- Part A: Single-ascending doses in healthy volunteers
- Part B: Single-ascending doses in participants with Stargardt Disease Type 1 (STGD1)
- Part C: Multiple doses in participants with Stargardt Disease Type 1 (STGD1)
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 1
Contactos y Ubicaciones
Estudio Contacto
- Nombre: City Therapeutics
- Número de teléfono: 857-219-5440
- Correo electrónico: clinicaltrials@citytx.com
Ubicaciones de estudio
-
-
Victoria
-
Melbourne, Victoria, Australia, 3004
- Reclutamiento
- Nucleus Network
-
Contacto:
- Nucleus Network Melbourne
- Número de teléfono: +61-1800-243-733
- Correo electrónico: melbourne@nucleusnetwork.com
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Key Inclusion Criteria (Part A):
- Willing and able to provide written informed consent form
- Be aged 18 to 45 years (inclusive) at the time of signing the informed consent form
- Generally healthy on medical history, exam, labs, and ECG
- BCVA 20/25 or better in each eye
- Serum retinol above protocol threshold
- Body weight ≥40 kg and BMI of 18.0 to 32.0 kg/m2
- Men and WOCBP must agree to use highly effective methods of contraception or practice abstinence from 30 days before the first dose of CITY-RBP4, throughout the study, and for at least 180 days after treatment with CITY-RBP4 or the last study visit, whichever is longer; men must refrain from donating or banking sperm during the same period
- Female participants who are not WOCBP should meet at least 1 of the following criteria: have undergone a documented hysterectomy, bilateral oophorectomy, and/or bilateral salpingectomy; have medically confirmed ovarian failure, or achieved postmenopausal status
Key Exclusion Criteria (Part A):
- Clinically significant ocular disease or prior ocular surgery that could interfere with safety assessments
- History of vitamin A deficiency, malabsorption, or chronic diarrhea
- Clinically significant cardiac, hepatic, renal, pulmonary, neurologic, or psychiatric disease
- Positive hepatitis B, hepatitis C, or HIV screening
- Prior RNAi/oligonucleotide therapy or recent investigational treatment
- Recent vitamin A-related supplements, retinoids, or medications affecting vitamin A metabolism
- Pregnancy or breastfeeding, if applicable
Key Inclusion Criteria (Parts B and C)
- Participants aged 12 to 45 years
- Clinical diagnosis of STGD1 with documented ABCA4 pathogenic/likely pathogenic variant
- Minimum BCVA is required in the study eye
- Subjects must have a defined aggregate atrophic lesion in 1 or both eyes
- Body weight ≥40 kg
- Able to complete key ophthalmic safety assessments and comply with study precautions
Key Exclusion Criteria (Parts B and C)
- Ocular conditions that could confound retinal imaging or safety evaluation
- Prior ocular gene therapy, stem cell therapy, or retinal implant
- Vitamin A deficiency or recent prohibited vitamin A-related treatments
- Recent interventional study participation
- Clinically significant non-ophthalmic disease, abnormal screening labs/ECG, or positive hepatitis B, hepatitis C, or HIV screening
- Pregnancy or breastfeeding, if applicable
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación Secuencial
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador de placebos: En Adultos Sanos (Parte A)
|
Saline (subcutaneous injection) |
|
Experimental: CITY-RBP4 in Healthy Adults (Part A)
|
siRNA (subcutaneous injection) |
|
Experimental: CITY-RBP4 in Participants with STGD1 (Parts B & C)
|
siRNA (subcutaneous injection) |
|
Comparador de placebos: In Participants with STGD1 (Parts B & C)
|
Saline (subcutaneous injection) |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Incidence, severity, and relationship of treatment-emergent adverse events (TEAEs)
Periodo de tiempo: Through study completion, up to Day 360
|
To evaluate the safety and tolerability of single and multiple doses of CITY-RBP4 in healthy adults and participants with Stargardt disease Type 1 (STGD1) |
Through study completion, up to Day 360
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Plasma concentrations of CITY-RBP4
Periodo de tiempo: Day 1 to Day 2
|
To characterize the pharmacokinetic (PK) profile of CITY-RBP4 after single and multiple doses of CITY-RBP4 in healthy adults and participants with STGD1 |
Day 1 to Day 2
|
|
Urine concentrations of CITY-RBP4
Periodo de tiempo: Part A and B only: Day 1 to Day 2
|
To characterize the pharmacokinetic (PK) profile of CITY-RBP4 after a single dose of CITY-RBP4 in healthy adults and participants with STGD1 |
Part A and B only: Day 1 to Day 2
|
|
Maximum plasma concentration (Cmax)
Periodo de tiempo: Day 1 to Day 2
|
To characterize the pharmacokinetic (PK) profile of CITY-RBP4 after single and multiple doses of CITY-RBP4 in healthy adults and participants with STGD1 |
Day 1 to Day 2
|
|
Time to maximum plasma concentration (Tmax)
Periodo de tiempo: Day 1 to Day 2
|
To characterize the pharmacokinetic (PK) profile of CITY-RBP4 after single and multiple doses of CITY-RBP4 in healthy adults and participants with STGD1 |
Day 1 to Day 2
|
|
Area under plasma concentration-time curve (AUC)
Periodo de tiempo: Day 1 to Day 2
|
To characterize the pharmacokinetic (PK) profile of CITY-RBP4 after single and multiple doses of CITY-RBP4 in healthy adults and participants with STGD1 |
Day 1 to Day 2
|
|
Terminal elimination half-life (t1/2)
Periodo de tiempo: Day 1 to Day 2
|
To characterize the pharmacokinetic (PK) profile of CITY-RBP4 after single and multiple doses of CITY-RBP4 in healthy adults and participants with STGD1 |
Day 1 to Day 2
|
|
Apparent clearance (CL/F)
Periodo de tiempo: Day 1 to Day 2
|
To characterize the pharmacokinetic (PK) profile of CITY-RBP4 after single and multiple doses of CITY-RBP4 in healthy adults and participants with STGD1 |
Day 1 to Day 2
|
|
Amount excreted unchanged (Ae)
Periodo de tiempo: Part A and B only: Day 1 to Day 2
|
To characterize the pharmacokinetic (PK) profile of CITY-RBP4 after a single dose of CITY-RBP4 in healthy adults and participants with STGD1 |
Part A and B only: Day 1 to Day 2
|
|
Change from baseline in plasma RBP4 concentrations
Periodo de tiempo: Up to Day 360
|
evaluate the pharmacodynamic (PD) effects of CITY-RBP4 on plasma retinol-binding protein 4 (RBP4) levels after single and multiple doses of CITY-RBP4 in healthy adults and participants with STGD1 |
Up to Day 360
|
|
Change from baseline in serum retinol concentrations
Periodo de tiempo: Up to Day 360
|
To evaluate the pharmacodynamic (PD) effects of CITY-RBP4 on serum retinol levels after single and multiple doses of CITY-RBP4 in healthy adults and participants with STGD1 |
Up to Day 360
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Medical Director, City Therapeutics
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- CITY-RBP4-01
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .